☰

Exolitus

Updating the operating model

Industry
Biotechnology
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Exolitus's published strategy and is not endorsed by, or produced in cooperation with, Exolitus. Company website

Strategic priorities

Exolitus operates across 4 stated priorities, with the most concrete near-term plan anchored on glioblastoma clinical enablement.

Transition Exo-3C-MP and Exo-3C-MG macrophage- and microglia-derived nanovesicles from preclinical IMP stage into Phase I human trials, requiring validated CMC data packages, durable potency assays, and unassailable audit trails for EMA/FDA filings.

Position Exolitus as a premier end-to-end exosome design, preclinical development, and large-scale manufacturing partner with modular, agile facilities capable of swapping between mammalian, plant, mushroom, and milk feedstocks on a unified digital orchestration layer.

Protect proprietary R&D data generated inside shared LSMU academic environments by establishing identity-based Zero Trust access, encrypted cloud data lakes, and air-gapped legacy instrument connectivity that keeps IP under absolute corporate control.

Challenges we see

  • Operations Manufacturing

    Manual Ultracentrifugation Bottleneck

    Lab-scale isolation depends on sequential ultracentrifugation (300g, 16,500g, then 100,000g cycles on a SORVALL WX Ultra Series rotor), which is labor-intensive, causes vesicle aggregation, and co-pellets contaminating macromolecular proteins.

    Without a transition to Tangential Flow Filtration (TFF) and chromatography with automated flow and pressure-differential monitoring, Exolitus cannot reach clinical-grade purity or commercial batch volumes for therapeutic and B2B cosmetic programs.

  • Digital Integration

    Decentralized Academic Data Islands

    Scientific data from NTA, Seahorse XFp, Cryo-TEM, and UPLC-MS instruments is stored on local LSMU workstations across multiple shared institute computers, with no central platform to correlate upstream cell culture parameters with downstream biological outcomes.

    This data fragmentation blocks Quality-by-Design correlation, limits real-time process visibility, and leaves proprietary IP subject to academic network sharing risks.

  • Compliance Regulatory

    GAMP5 / Annex 11 Compliance Deficit

    Current infrastructure relies on unvalidated open-source tools, unencrypted academic directories, and paper logbooks lacking electronic signatures, secure audit trails, or GAMP5-validated cloud hosting required for IMP-enabling clinical applications.

    EMA/FDA inspection of clinical trial submissions for Exo-3C-MP could result in rejection due to data integrity gaps under 21 CFR Part 11 and EU GMP Annex 11.

  • Operations Manufacturing

    Raw Material Heterogeneity & Process Drift

    Exolitus processes a highly diverse raw material portfolio spanning human macrophages, bovine colostrum, lemon balm leaves, raspberries, and mushrooms, each subject to genetic, cultivation, and harvest-time variability that drives invisible drift in active exosome yield and potency.

    Without inline analytics and automated feedback control, identical downstream extraction parameters yield variable cargo loading, jeopardizing batch-to-batch reproducibility and B2B customer trust.

  • Digital Integration

    Vendor-Locked Instruments & Manual Transcription

    LSMU lab instruments operate on proprietary, vendor-locked software ecosystems with no OPC UA layer; researchers manually export raw files via USB, calculate in Excel, and transcribe values into paper logs.

    Manual workflows cap throughput for the preclinical contract services unit, introduce transcription errors, and prevent the company from securing high-volume mid-tier and large pharma screening contracts.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Closed-System Bioprocess Scale-Up

    Adherent primary cell culture (macrophages for Exo-3C-MP, stem cells for Exo-7A-SC) in 2D flasks plus open-system ultracentrifugation cannot meet clinical-grade demand and risks vesicle damage during scale-up to 3D bioreactors.

    Deploy closed Tangential Flow Filtration with inline particle-size monitoring and single-use bioreactors instrumented for dissolved O2, pH, and agitation control, scaling production capacity while preventing batch loss.

  2. Regulatory Audit Trail & Data Integrity

    Paper notebooks, unvalidated open-source tools, and unencrypted academic directories cannot satisfy 21 CFR Part 11 or EU GMP Annex 11 requirements for IMP-enabling activities on Exo-3C-MP.

    Implement validated bioprocess Control on a GAMP5-compliant AWS/Azure environment to deliver automated electronic signatures, ALCOA+ audit trails, and validated workflows ready for EMA/FDA inspection.

  3. Unified Lab Data Platform & LIMS

    Critical data from NTA, Cryo-TEM, Seahorse XFp, and UPLC-MS lives on disconnected academic workstations, blocking correlation between upstream cell culture and downstream biological outcomes and slowing contract-service report delivery.

    Build an OPC UA-enabled industrial data platform with ontology-driven pipelines that ingest every instrument into a single source of truth, enabling LIMS-grade traceability and automated report generation for B2B clients.

  4. Modular Multi-Feedstock Manufacturing

    A single shared pilot facility processes human cell lines alongside plant, mushroom, and bovine raw materials, creating GMP cross-contamination risk and rigid lines that cannot scale across the cosmetic, food, and therapeutic SKUs.

    Engineer a Plug & Produce manufacturing architecture using the VDI/VDE/NAMUR 2658 Module Type Package (MTP) standard so extraction modules can be hot-swapped on a unified orchestration layer without PLC reprogramming.

  5. Predictive Digital Twin for Bioprocess De-Risking

    Cell-membrane cloaking, organelle targeting, and size-dependent potency are highly sensitive to bioreactor fluid dynamics, shear stress, and membrane-binding kinetics, yet Exolitus optimizes them through expensive wet-lab iteration with a lean 8-person team.

    Build a Digital Twin for bioreactor and purification lines that simulates barrier-crossing efficiency, cardiomyocyte targeting, and shear effects to drastically reduce physical experiments and accelerate prototype-to-production.

What we'd propose

  • Digital Lab

    GAMP5 Data Integrity & bioprocess Control Deployment

    End-to-end paper-to-performance transformation that replaces manual notebooks and unvalidated academic tools with bioprocess Control on a validated GAMP5 cloud environment, ready for EMA/FDA inspection of the Exo-3C-MP IMP package.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    TechBio Industrial Data Platform & LIMS

    Ontology-driven data lakehouse with OPC UA pipelines that unify NTA, Seahorse XFp, Cryo-TEM, and UPLC-MS streams into a single source of truth with LIMS-grade traceability for both R&D and contract services.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    Closed-System Bioprocess Retrofit & PAT Control

    IT/OT retrofitting of upstream cell culture and downstream purification lines, replacing manual ultracentrifugation with closed TFF and instrumented single-use bioreactors under closed-loop PAT control.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Digital CDMO

    Modular Plug & Produce Manufacturing (MTP)

    VDI/VDE/NAMUR 2658 Module Type Package implementation that turns Exolitus's pilot extraction lines into hot-swappable modules orchestrated from a unified digital layer, enabling rapid switching between human, plant, mushroom, and bovine feedstocks.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Adaptive Digital Twin for Exosome Bioprocess

    Multi-year roadmap delivering an Adaptive Digital Twin of the bioreactor, purification, and characterization lines, simulating fluid dynamics, shear stress, vesicle aggregation, and barrier-crossing kinetics to de-risk clinical and B2B programs.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Exolitus's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data Integrity & Compliance 25 → 90
Currently relies on paper logs and unvalidated open-source tools; must reach GAMP5 / Annex 11 / 21 CFR Part 11 readiness for Exo-3C-MP IMP submissions.
Lab Instrument Connectivity 20 → 85
NTA, Seahorse XFp, Cryo-TEM, and UPLC-MS are vendor-locked silos with manual USB exports; OPC UA backbone will unify them.
Manufacturing Automation 30 → 80
Sequential ultracentrifugation and manual extraction must shift to closed TFF and instrumented single-use bioreactors with PAT loops.
Process Modularity (MTP) 25 → 85
Pilot lines are rigid; Plug & Produce architecture is required to hot-swap human, plant, mushroom, and bovine feedstocks.
Cybersecurity & IP Sovereignty 30 → 85
IP currently sits on shared LSMU academic networks; Zero Trust identity and Closed Connectivity Solution will isolate proprietary data.
Predictive Analytics & Digital 15 → 75
No predictive simulation today; Adaptive Digital Twin can de-risk size-distribution and barrier-crossing performance ahead of clinical trials.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Exolitus, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].